Cargando…

(18)F-PSMA-1007 PET/CT Performance on Risk Stratification Discrimination and Distant Metastases Prediction in Newly Diagnosed Prostate Cancer

OBJECTIVE: To evaluate the prediction performance of (18)F-PSMA-1007 PET/CT and clinicopathologic characteristics on prostate cancer (PCa) risk stratification and distant metastatic prediction. MATERIALS AND METHODS: A retrospective analysis was performed on 101 consecutively patients with biopsy or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhuonan, Zheng, Anqi, Li, Yunxuan, Dong, Weixuan, Liu, Xiang, Yuan, Wang, Gao, Fan, Duan, Xiaoyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581554/ https://www.ncbi.nlm.nih.gov/pubmed/34778079 http://dx.doi.org/10.3389/fonc.2021.759053

Ejemplares similares

Evaluation of a radiomics nomogram derived from Fluoride-18 PSMA-1007 PET/CT for risk stratification in newly diagnosed prostate cancer
por: Wang, Zhuonan, et al.
Publicado: (2022)

The (18)F-PSMA-1007 PET/CT performance on metastasis status and therapy assessment in oligo-metastasis prostate cancer
por: Wang, Zhuonan, et al.
Publicado: (2022)

Evaluating the value of (18)F-PSMA-1007 PET/CT in the detection and identification of prostate cancer using histopathology as the standard
por: Luo, Liang, et al.
Publicado: (2023)

The prognostic value of (18)F-PSMA-1007 PET/CT in predicting pathological upgrading of newly diagnosed prostate cancer from systematic biopsy to radical prostatectomy
por: Zheng, Anqi, et al.
Publicado: (2023)

(18)F-PSMA-1007 PET/CT-derived semi-quantitative parameters for risk stratification of newly diagnosed prostate cancer
por: Dong, Siying, et al.
Publicado: (2022)

Impact of non-regional lymph node metastases accurately revealed on (18)F-PSMA-1007 PET/CT in the clinical management of metastatic hormone-sensitive prostate cancer
por: Jiang, Zhangdong, et al.
Publicado: (2023)

Isolated Rectal Metastases from Locally Advanced Carcinoma Prostate Detected by (18) F-PSMA-1007 PET/CT
por: Singh, Shashank Shekhar, et al.
Publicado: (2022)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
por: Iversen, Peter, et al.
Publicado: (2022)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

(18)F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report
por: Wang, Long, et al.
Publicado: (2021)

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
por: Zhang, Yan-Nan, et al.
Publicado: (2022)

Non-prostate uptake on (18)F-PSMA-1007 PET/CT: a case of myeloma
por: Veerasuri, Sowmya, et al.
Publicado: (2020)

Dose-reduced [(18)F]PSMA-1007 PET is feasible for functional imaging of the renal cortex
por: Valind, Kristian, et al.
Publicado: (2021)

(18)F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis
por: Ferrari, Matteo, et al.
Publicado: (2021)

Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
por: Mingels, Clemens, et al.
Publicado: (2022)

Meta-analysis of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and (68)Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
por: Yu, Wenxiao, et al.
Publicado: (2023)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Optimization of [(18)F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer
por: Trägårdh, Elin, et al.
Publicado: (2020)

Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET
por: Maurer, Alexander, et al.
Publicado: (2022)

The value of (18)F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer
por: Hong, Jun-jie, et al.
Publicado: (2020)

Heterogeneous uptake of (18)F-FDG and (18)F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis
por: Hu, Yuan, et al.
Publicado: (2023)

Assessing the accuracy of [(18)F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients
por: Ingvar, Jacob, et al.
Publicado: (2022)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Diagnostic Role of (18)F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
por: Awenat, Salam, et al.
Publicado: (2021)

Risk of metastatic disease using [(18)F]PSMA-1007 PET/CT for primary prostate cancer staging
por: Chikatamarla, Venkata Avinash, et al.
Publicado: (2021)

An exploratory study of unexplained concentration of (18)F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging
por: Dang, Jun, et al.
Publicado: (2023)

Biokinetics and dosimetry of (18)F‐PSMA‐1007 in patients with prostate cancer
por: Hvittfeldt, Erland, et al.
Publicado: (2022)

Skeletal (18)F-PSMA-1007 uptake in prostate cancer patients
por: Janssen, Jorinde, et al.
Publicado: (2023)

Intra-Individual Comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the Evaluation of Patients With Prostate Cancer
por: Zhou, Xing, et al.
Publicado: (2021)

Evaluation of (18)F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
por: Zhou, Xing, et al.
Publicado: (2021)

Preclinical comparative study of [(18)F]AlF-PSMA-11 and [(18)F]PSMA-1007 in varying PSMA expressing tumors
por: Piron, Sarah, et al.
Publicado: (2022)

Freely Available, Fully Automated AI-Based Analysis of Primary Tumour and Metastases of Prostate Cancer in Whole-Body [(18)F]-PSMA-1007 PET-CT
por: Trägårdh, Elin, et al.
Publicado: (2022)

Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on (18)F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies
por: Vollnberg, Bernd, et al.
Publicado: (2022)

Diagnostic value of integrated (18)F-PSMA-1007 PET/MRI compared with that of biparametric MRI for the detection of prostate cancer
por: Zeng, Yuping, et al.
Publicado: (2022)

Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

An Explorative Study of the Incidental High Renal Excretion of [(18)F]PSMA-1007 for Prostate Cancer PET/CT Imaging
por: Allach, Youssra, et al.
Publicado: (2022)

Recurrent Prostate Cancer Diagnostics with (18)F-PSMA-1007 PET/CT: A Systematic Review of the Current State
por: Saule, Laura, et al.
Publicado: (2022)

[(18)F]PSMA-1007 PET is comparable to [(99m)Tc]Tc-DMSA SPECT for renal cortical imaging
por: Valind, Kristian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9mhunqn5932e6dncvlp8s1u4b4